{{Rsnum
|rsid=2242048
|Gene=SLC28A1
|Chromosome=15
|position=84935179
|Orientation=minus
|GMAF=0.07208
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLC28A1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 80.5 | 16.8 | 2.7
| HCB | 83.9 | 16.1 | 0.0
| JPT | 88.5 | 11.5 | 0.0
| YRI | 93.2 | 6.1 | 0.7
| ASW | 87.7 | 12.3 | 0.0
| CHB | 83.9 | 16.1 | 0.0
| CHD | 92.7 | 6.4 | 0.9
| GIH | 81.2 | 17.8 | 1.0
| LWK | 98.2 | 1.8 | 0.0
| MEX | 82.8 | 15.5 | 1.7
| MKK | 98.1 | 1.9 | 0.0
| TSI | 85.3 | 14.7 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2242048
|Name_s=SLC28A1:1383C>T
|Gene_s=SLC28A1
|Feature=Exon/Syn
|Evidence=PubMed ID:15224082
|Annotation=Risk or phenotype-associated allele: None. Phenotype: Variants identified in a screen of 13 genes involved in the gemcitabine drug metabolic pathway. For the SLC28A1:1383C>T SNP, the T allele was at frequency was 0.08 and 0.05 in Europeans and Africans, respectively. There was no significant difference between ethnic groups in genotype frequency distribution (p > 0.05). Study size: 185. Study population/ethnicity: Healthy, unrelated blood donors of European (n = 91) and African (n = 94) descent. Significance metric(s): Not significant, p > 0.05. Type of association: GN.
|Drugs=gemcitabine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110722
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2242048
|overall_frequency_n=9680
|overall_frequency_d=10758
|overall_frequency=0.899795
|n_genomes=54
|n_genomes_annotated=0
|n_haplomes=101
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}